Effectiveness of sublingual use of 400 mcg prostaglandin E1 for first trimester surgical abortion according to parity: a retrospective study.
OBJECTIVE
The aim of this paper was to evaluate the effectiveness of sublingual use of misoprostol in women undergoing first trimester surgical abortion. Special consideration was given in a sub-group analysis according to parity.


METHODS
A retrospective study was conducted, enrolling patients during 2006-2009. Pregnancies less than 12 weeks of gestation were exclusively included. Our sample was divided in: group 1, in which we included women who had received 400 mcg of misoprostol sublingually two hours before surgical abortion and group 2, with no use of misoprostol. Cervical dilatation and estimated blood loss (EBL) were compared between the two groups. Moreover, a sub-group analysis of the former parameters was made separately in nulliparous and multiparous women.


RESULTS
Out of 79 patients included, 48 (60.75%) received misoprostol, while 31 (39.25%) did not. Cervical dilatation was significantly higher in group 1 (6.4±2.1 mm vs. 4.7±1.7 mm in group 2, P=0.001), while EBL was significantly lower in the same group (105.0±22.1 mL vs. 120.3±24.2 mL for group 2, P=0.005). Concerning the sub-analysis, cervical dilatation was significantly increased and EBL was significantly lower in multiparous receiving misoprostol comparing with those who did not (P=0.001 and P=0.002, respectively). However, the same parameters did not differ significantly between the two sub-groups of nulliparous women.


CONCLUSIONS
Sublingual administration of 400mcg misoprostol is effective concerning cervical ripening and EBL in women undergoing first trimester surgical abortion. According to the results of the present clinical trial prostaglandin E1 is more effective in multiparous group of women.
th Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Thessaloniki, Greece - petustam@mail.gr.
I
I
Kalogiannidis
G
G
Gitas
S
S
Petousis
C
C
Margioula-Siarkou
T
T
Xenidis
T
T
Dagklis
N
N
Prapas
T
T
Agorastos
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000494:pharmacology*; D000028:Abortion, Induced / Q000379:methods*; D000286:Administration, Sublingual; D000328:Adult; D020070:Cervical Ripening / Q000187:drug effects*; D004107:Dilatation and Curettage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage / Q000494:pharmacology*; D010298:Parity; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011292:Premedication; D012189:Retrospective Studies; D055815:Young Adult
D000020:Abortifacient Agents, Nonsteroidal; D016595:Misoprostol